DANIEL R. PASSERI - 06 Mar 2024 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Daniel Passeri by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
06 Mar 2024
Net transactions value
$0
Form type
4
Filing time
08 Mar 2024, 16:00:09 UTC
Previous filing
16 Aug 2023
Next filing
18 Dec 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +400,000 $0.000000 400,000 06 Mar 2024 Common Stock 400,000 $1.94 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option becomes exercisable in eight equal semi-annual installments beginning on September 6, 2024.